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Abstract 
 
trans-4-Hydroxy-L-proline (2.2) was converted to a key oxazolidinone precursor (2.1) by 
an improved Greenwood’s procedure.47,48 The diastereofacial selective property of (2.1) 
led to a stereo-controlled 1,3-dipolar cycloaddition and gave a single tricyclic 
III 
 
diastereomer (2.20). The N-O bond of the resulting isoxazoline (2.20) was cleaved by a 
reductive ring-opening, followed by an elimination to give enone (2.26). The enone (2.26) 
was converted to a -silanol (2.33) by a nucleophillic addition with LiCH2Si(CH3)3 and 
then an acetylation to (2.27) was attempted. 
Addition of Gilman reagent to the enone (2.26) resulting a diastereoselective 1,4-
nucleophillic addition and afforded the C-2,C-3 trans, C-3,C-4 cis sterically favoued 
bicyclic pyrrolidine (2.38) as the only diastereomer. All that remains for the synthesis of 
kainic acid (1.1) are olefination, ring-opening of carbamate, oxidation and deprotection. 
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1. Introduction 
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1.1 Structure and Isolation 
(-)--Kainic acid (1.1) (figure 1.1) (originally known as digenic acid) is a five membered 
cyclic amino dicarboxylic acid, which consists of a pyrrolidine ring with 3 asymmetric 
centres – C-2,C-3 & C-4, with the S, S and S or R related configuration respectively. 
Different substituents at C-4 gives rise to a series of the kainoid members (figure 1.2).1 
(-)--Kainic acid (1.1) was the earliest kainoid member to be isolated by Murakami in 
1953 from the Japanese marine alga Digenea simplex2, together with its C-4 epimer  (+)-
-Allokainic acid (1.2).  It has also been found in the related alga Centrocerus 
clavulatum3 and in the Alsidium Helminthocorton (known as Corsican moss).4,5 The 
structure was deduced by Japanese chemistry groups by classical chemical degradation 
methods in the mid 1950’s,6,7,8. The stereochemistry of the pyrrolidine ring was deduced 
by Morimoto in 1955 using chemical studies,9 and also confirmed by single crystal X-ray 
analysis.10,11 Subsequently the absolute stereochemistry was established by Oppolzer and 
Thirring from their total synthesis of (-)--Kainic acid (1.1).12  
3 
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1.2 Biological Properties 
Kainoid amino acids have notable insecticidal, anthelmintic and neuroexcitatory 
properties. Kainic acid (1.1) acts as the key active component in the alga Digenea simplex, 
which has been used as an anthelmintic in Japan for more than a thousand years. Its 
anthelmintic effect is about 10 times more potent than santonin (an anti-ascarid drug).
10
 
The anthelmintic function of kainic acid (1.1) depends on the stereochemistry of the C-3 
and C-4 substituents; the anthelmintic effect of allokainic acid (1.2) is very weak. The 
anthelmintic activity of all known stereoisomers of kainic acid (1.1) is also very weak 
compared with (-)--kainic acid (1.1) itself.13 
Kainic acid (1.1) is used for neuroscience research. The pharmacological effects observed 
after injection of kainoids is similar to that of patients suffering from neurodegenerative 
diseases such as epilepsy,
14
 Huntington’s chorea15,16 and Alzheimer’s disease.17 In 2000, 
the price of kainic acid (1.1) rose significantly due to shortage of supply. 
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1.3 Biosynthesis 
Wright has investigated the biosynthesis pathway of domoic acid (1.3),
18
 by performing 
labelling experiments. [1-
13
C] Acetate and [1,2-
13
C] acetate proved the pyrrolidine rings 
of the kainoids were formed by a novel condensation of an isoprenoid unit with a 
glutamic acid derivative. For instance, domoic acid (1.3), is formed by cyclisation of a 
glutamic acid derivative (1.17) (where X is a leaving group), with a geranyl 
pyrophosphate (1.18) (Scheme 1.1). 
 
Wright also suggested kainic acid (1.1) was generated in a similar manner (from 
isopentenyl pyrophosphate (1.19) instead of geranyl pyrophosphate (1.18)) (Scheme 
1.2).
18
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1.4 Previous Syntheses 
Early syntheses of kainic acid (1.1) were inefficient and nonstereoselective,
19,20
 the need 
for stereocontrol of the C-2, C-3 and C-4 of the pyrrolidine makes the synthesis of (-)--
kainic acid challenging. To date, more than 50 synthetic routes have been developed. 
Some of these have been reviewed by Parsons.1 A numbers of these syntheses involved a 
stereocontrolled intramolecular ene reaction as a key step for the formation of the tri-
substituted pyrrolidine framework. Some of the stereocontrolled syntheses will be 
discussed in this chapter. 
The first enantioselective total synthetic route to kainic acid (1.1) was developed by 
Oppolzer and Thirring
 
in 1982.
12
 The carbamate (1.20) was prepared by Boc protecting 
commercially available (S)-(+)-5-ethyl glutamate (1.21). After silylation and alkylation of 
carbamate (1.20), the saturated ester (1.22) then eliminated to a 1,6-diene intermediate 
(1.23) (Scheme 1.3). 
8 
 
 
The 1,6-diene intermediate (1.23) was then cyclised to a kainoid pyrrolidine skeleton 
(1.24) by an intramolacular ene-reaction, forming a new C-3,C-4 bond. 
1
H NMR analysis 
proved the configurations of the isopropenyl group and ethoxy carboyl on C-3 and C-4 
were cis related. After the removal of the protecting groups and oxidation of the alcohol, 
the desired (-)--kainic acid (1.1) was afforded in 5% overall yield from (S)-(+)-5-ethyl 
glutamate (1.21) (Scheme 1.4). This remains one of the shortest synthetic routes for 
kainic acid (1.1), with only 6 steps involved. 
 
9 
 
Five years later, Knight and co-workers reported the second total synthetic route to kainic 
acid (1.1).
21,22
 L-Aspartic acid (1.25) was converted to a protected -amino acid 
derivative (1.26) in five steps, then it was coupled with a tetrahydropyranyl protected 
chloride fragment (1.27) to afford adduct (1.28). After removal of the tetrahydropyranyl 
protecting group and lactonisation, the azalactone precursor (1.29) was prepared (Scheme 
1.5). 
 
10 
 
The key Claisen rearrangement step resulted in stereoselective formation of the new C-
3,C-4 bond, to afford a tri-substituted pyrrolidine carboxylic acid (1.30) in 55% yield, 
without any other isomers being detected. After carrying out an Arndt-Eistert 
homologation, desilylation, oxidation and removal of the carbamate, kainic acid (1.1) was 
successfully synthesised (Scheme 1.6). 
Yoo has developed a synthetic route for kainic acid (1.1) which also involved the use of 
an ene-reaction in 1990.
23
 The key vinyl allylic acetate precursor (1.31) was prepared by 
coupling vinylamino alcohol (1.32) with allylic chloride (1.33), followed by benzoylation 
(Scheme 1.7). 
11 
 
 
The intramolecular cyclisation of vinyl allylic acetate precursor (1.31) and subsequent 
carbonylation were catalysed by Pd(dba)2, and, after hydrolysis with H2O and 
esterification with CH2N2, two major pyrrolidine isomers (1.34) and (1.35) were formed 
in 35% and 25% yield, respectively (Scheme 1.8). One minor bicyclic product (1.36) was 
also obtained in 10% yield, due to a second cyclisation of the C-3 acyl onto the alkene 
double bond. After the elaboration of isomers (1.34) and (1.35), allokainic acid (1.2) and 
kainic acid (1.1) were formed respectively (Scheme 1.9). 
12 
 
 
 
The synthesis of kainic acid developed by Ogasawara also involved the use of an 
intramolecular ene-reaction.
24
 The (+) or (-) - enantiomers of optically pure ketodicyclo-
13 
 
pentadiene (KDP) were used as starting materials for the preparation of the tricyclic 
precursors (1.37) and (1.38). A one-pot retro-Diels Alder reaction gave the monocyclic 
carbamate intermediate (1.39) containing a 1,6-diene system which underwent 
spontaneous conversion to a cis trisubstituted pyrrolidine (1.40) via an intramolecular 
ene-reaction under the same conditions (Scheme 1.10). The bicyclic pyrrolidine (1.40) 
was used as a framework for the synthesis of kainic acid (1.1). 
 
Ogasawara reported another synthesis of kainic acid in 2000,
25
 which consisted of a 
Chugaev syn-elimination and intramolecular ene-reaction. The key xanthate precursor 
14 
 
(1.41) was prepared from an enantiopure (+)-cis-4-carbobenzoxyamino-2-cyclopentenol 
(1.42) in 58% overall yield in six steps (Scheme 1.11). 
 
Then the xanthate (1.41) was converted to a trisubstituted pyrrolidine (1.43) by 
employing a Chugaev syn-elimination and intramolecular ene-reaction via the transient 
1,6-diene intermediate (1.44) in one-pot. N.Ö .e experiments proved that only one 
diastereomer had been formed and all substituents on C-2, C-3 and C-4 were cis related. 
After elaboration of the pyrrolidine framework (1.43), kainic acid (1.1) was obtained in 
13% overall yield from alcohol (1.42) (Scheme 1.12). 
15 
 
Ganem has developed a total synthesis of kainic acid (1.1) which involves the use of an 
asymmetric,
26
 magnesium bis-oxazoline catalyzed ene-cyclisation as a key step for the 
construction of the pyrrolidine framework. Pure stereoisomer 1,6-diene (1.45) was 
prepared from N-prenylamine in two steps and the intramolecular ene-cyclisation of (1.45) 
in the presence of ligand (1.46) occurred with high diastereoselectivity, favouring 
pyrrolidine (1.47) over its trans isomer (1.48) (>20:1). The mixture of pyrrolidine (1.47) 
and (1.48) was then hydrolysed and converted to nitrile (1.49) by using Schwartz’s 
reagent and nitrilation. After the hydrolysis of both nitrile and ester, followed by 
epimerization with base, kainic acid (1.1) was afforded in a high overall yield exceeding 
20% (Scheme 1.13). 
16 
 
Takano has shown great interest in the synthesis of kainic acid by developing a total of 
four enantioselective approaches. The first synthetic approach involved an enantio- and 
diastereo-selective intramolecular 1,3-dipolar cyclisation as a key step.
27
 The key 
aziridine ester precursor (1.50) was prepared from (S)-2-(benzyloxymethyl)oxirane (1.51) 
in 4 steps (Scheme 1.14). 
 
17 
 
The intramolecular 1,3-dipolar cyclisation was performed by heating the aziridine ester 
precursor (1.50) in xylene at 310 
o
C for 5 min, to give the bicyclic pyrrolidine (1.52) with 
all cis configuration. The authors postulate that the ylid adopts conformation (1.53), 
placing the benzyloxymethyl substituent in a pseudoequatorial orientation (Scheme 1.15). 
 
Following further elaboration of pyrrolidine (1.52) including the epimerisation at C-2 by 
using base, kainic acid (1.1) was prepared. 
In the same year, Takano reported the second synthesis of kainic acid (1.1).
28
 Starting 
from diethyl L-tartrate (1.54) to generate the aldehyde (1.55) key precursor, followed by a 
diastereoselective intramolecular Diels-Alder reaction to give the tricyclic adduct (1.56) 
with cis C-3/C-4 juncture, caused by the carbamate sp
2
-like planar configuration at 
18 
 
nitrogen allowing [4+2] overlap only in the endo conformation. After elaboration to 
the tricyclic pyrrolidine (1.56), kainic acid (1.1) was achieved (Scheme 1.16). 
 
Baldwin has developed a synthetic route to kainic acid (1.1) based on a cobalt-mediated 
cyclisation as a key step,
29
 for the stereoselective construction of the pyrrolidine structure. 
Starting from epoxide (1.57) (which is readily accessible through the corresponding 
allylic alcohol by the Sharpless epoxidation) convertion to the key acyclic iodide 
precursor (1.58) was carried out in six steps.
30,31
 Carrying out a cobaloxime mediated 
cyclisation on (1.58) led to the formation of a novel C-3,C-4 bond, which gave the 
separable stereoisomers (1.59) and (1.60) in a 50% and 30% yield respectively. Both 
pyrrolidine frameworks (1.59) and (1.60) were deprotected then oxidised to give (-)--
19 
 
kainic acid (1.1) and (+)-allokainic acid (1.2) respectively (Scheme 1.17). 
In 1993, Takano also reported a synthetic route for both kainic acid (1.1) and allokainic 
acid (1.2).
32
 This synthesis employed a radical based enantioselective cyclisation to 
construct the C-3,C-4 bond of the pyrrolidine ring. The key vinyl iodide precursor (1.61) 
was obtained from L-serine. A highly diastereoselective radical intramolecular cyclisation 
of the precursor (1.61) using tributyltin hydride and AIBN led to the formation of 
pyrrolidine (1.62) in an excellent yield of 86% (scheme 1.18). 
20 
 
After the hydrolysis of pyrrolidine (1.62), carboxylic acid (1.63) was then treated with 
BF3·OEt2 in dichloromethane, when concommitant C-3 directed intramolecular 
protodesilylation, methylation and deprotection led to a single diastereomer (1.64) , an 
allokainic acid precursor, in 57% yield (Scheme 1.19). 
Pyrrolidine (1.62) was elaborated to carboxylic acid (1.65) and treatment with BF3·OEt2 
in dichloromethane similarly led to a C-2 directed intramolecular proto-desilylation. 
After methylation, the kainic acid precursor (1.66) was prepared in 58% yield (together 
with its C-4 epimer (1.67) in 11%). (Scheme 1.20) 
21 
 
 
Benetti developed a synthetic route for kainic acid in 1991,
33
 which involved the 
construction of the pyrrolidine C-3 and C-4 bond by tandem Michael reactions. By 
cyclising a secondary amine (1.68) (which was generated from D-serine) with an 
electron-withdrawing diene (1.69) generated from the nitro compound (1.70) in situ, a 
trisubstituted pyrrolidine adduct (1.71) with a trans C-2,C-3 and cis C-3,C-4 
configuration was formed in 88% yield. The allylic nitro group was removed regio- and 
stereo- selectively by a hydride transfer reaction with a palladium(0) catalyst developed 
by Ono, to give kainic acid precursor (1.72) in quantitative yield (Scheme 1.21).
34
 
22 
 
An enantioselective route to kainic acid (1.1) involving a Pauson-Khand reaction as the 
key step was developed by Takano in 1993.
35
 (R)-4-Benzyloxy-1-butyn-3-ol was 
converted to the tertiary carbamate (1.73) in four steps. Treatment of (1.73) with dicobalt 
octacarbonyl gave the cobalt complex (1.74). Treatment of (1.74) with N-
methylmorpholine N-oxide (NMO) gave the bicyclic enones (1.75) and (1.76) as an 
inseparable mixture in 85% yield. After reduction and removal of the THP group to form 
the mixture (1.75) and (1.76) (Scheme 1.22), the desired bicyclic adduct (1.77) was 
formed in 60% yield. 
23 
 
The subsequent elaboration of the bicyclic ketone (1.77), included lactone formation and 
then a facile cleavage of the cyclic lactone, led to kainic acid (1.1) being prepared in 5 
steps (Scheme 1.23). 
24 
 
 
Yoo has also developed a similar pathway towards kainic acid based on the Pauson-
Khand reaction.
36
 The key intermediate (1.78) was prepared from the vinyl glycine 
derivative (1.79), followed by the Pauson Khand reaction with dicobalt octacarbonyl, 
which formed an inseparable mixture of two bicyclic enone diastereoisomers (1.80) and 
(1.81) (1.7:1) in 95% yield (Scheme 1.24). The mixture of (1.80) and (1.81) was 
converted to kainic acid (1.1) in six steps. 
 
25 
 
Monn has developed a synthetic route to kainic acid (1.1) which involved a 
stereocontrolled thiazolium ylide dipolar cycloaddition approach.
37,38
 The pyrrolidine C-
3,C-4 bond was constructed by the cyclisation of thiazolium ylide bromide (1.82) 
(prepared from thiazolium in situ) with 2-cyclopentenone to give a separable mixture of 
tetracyclic isomers (1.83) and (1.84) in good yield (70-80%). By means of reductive 
cleavage of the C-S bond with tri-n-butyltin hydride followed by hydrolysis in situ, 
protection of the nitrogen, methylation and elimination, the bicyclic trans C-2,C-3, cis C-
3,C-4 pyrrolidine framework (1.85) was constructed (Scheme 1.25). 
 
After the oxidative ring opening of (1.85) with RuO4 under Sharpless conditions, 
followed by elaboration to the pyrrolidine (1.86), kainic acid (1.1) was prepared in 8% 
26 
 
overall yield from 2-cyclopentenone (Scheme 1.26). 
 
A synthesis of kainic acid (1.1) employing titanium-mediated diene metallabicyclisation 
was developed by Taylo.
39,40
 The key 1,6 diene precursor (1.87) was obtained by reacting 
the alkene (1.88) (generated from L-serine) with allylic chloride (1.89), followed by a 
diastereoselective cyclisation in the presence of Ti(O
i
Pr)4 and iodination to give all cis 
trisubstituted pyrrolidine (1.90) in 56% yield. After elaboration to the pyrrolidine (1.90) 
including an epimerisation at C-2 with base, kainic acid (1.1) was formed in 3.5% yield 
over 12 steps (Scheme 1.27). 
27 
 
 
Lautens has used a diastereoselective methylenecyclopropane ring expansion method for 
the total synthesis of kainic acid (1.1).
41
 The desired diastereomer (1.91) was prepared by 
a MgI2-mediated ring expansion of methylene cyclopropylamide (1.92) in the presence of 
chiral sulfinimine (1.93), followed by a stereocontrolled hydroboration with 9-BBN and 
oxidative workup to give pyrrolidine (1.94).
47
 By this approach kainic acid (1.1) was 
successfully synthesized in 13 steps, with an overall yield of 15% from methylene 
cyclopropylamide (1.92) (Scheme 1.28). 
28 
 
Hodgson has developed a synthetic route for kainic acid (1.1) which involves a radical 
rearrangement.
43
 The dienyl sulfone radical acceptor (1.95) was generated from 
commercially available materials (N-Boc pyrrole and tosyl ethyne) in one step. Treatment 
of (1.95) with 2-iodoethanol in the presence of Bu3SnH and Et3B led to a radical 
mediated addition and rearrangement to give sulfone (1.96) in 78% yield. Sulfone (1.96) 
was then converted to enol ether (1.97) by ozonolysis, Swern oxidation, Boc replacement 
and Julia elimination (Scheme 1.29). 
 
29 
 
After the acid-catalysed hydration of enol ether (1.97), lactol (1.98) was formed with the 
desired trans C-2,C-3, cis C-3,C-4 configuration for kainoids. A further ring opening led 
to the formation of trisubstituted kainic acid precursor (1.99) (Scheme 1.30). 
 
Anderson achieved a total synthesis of kainic acid (1.1),
44
 by using an aza-[2,3]-Wittig 
sigmatropic rearrangement as the key step. Beginning with commercially available 3-
butyne-1-ol, the key achiral aza-[2,3]-Wittig precursor (1.100) was synthesized in five 
steps. Treatment of (1.100) with LDA led to aza-[2,3]-Wittig rearrangement and formed 
amino acid derivative (1.101) in 78% yield. After protodesilylation of (1.101) with H2O 
under basic conditions and a further treatment with TBAF, alkene (1.102) was obtained 
in 59% overall yield (Scheme 1.31). 
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Iodolactonization provided a mixture of diastereomers of the lactone (1.103) and (1.104) 
in a 7:1 ratio. The stereo configurations of C-2,C-3 and C-4 of the major diastereomer 
(1.103) were verified by n.Ö .e analysis, and shown to be the same as the pyrrolidine ring 
of kainic acid (1.1). Deprotection and base-induced ring opening of the lactone followed 
by a 5-exo-tet cyclization gave the pyrrolidine kainic acid precursor (1.105) in 86% yield 
(Scheme 1.32). 
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Two years later the same group reported a stereocontrolled approach to (-)-kainic acid. 
Starting with N-Boc glycine methyl ester (1.106),
47
 the rearrangement precursor (1.107) 
was prepared in three steps, followed by an aza-[2,3]-Wittig rearrangement which was 
initiated with KH and 18-crown-6 in THF to give a diastereomerically pure product 
(1.108) in 47% yield. Then (1.108) was converted to the amino acid derivative (1.101) 
(an intermediate in the previous synthesis) in 4 steps. Kainic acid (1.1) was successfully 
synthesized by means of his earlier procedure (scheme 1.33). 
The most recent total synthesis of kainic acid (1.1) was developed by Fukyama in 2007.
46
 
The trisubstituted pyrrolidine ring was constructed by a ring-closing metathesis of an 
acrylate diene (1.109) (generated from oxazolidinone (1.110)) by a Hoveyda Grubbs’ 
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second generation catalyst (1.111) to give the ,-unsaturated lactone (1.112) (scheme 
1.34). 
Treatment with LiHMDS in DMF initiated an intramolecular Michael addition to (1.112), 
forming the desired pyrrolidine derivative (1.113) together with its C-2 epimer (1.114) in 
a 91:9 ratio respectively, in 95% yield. After ring-opening to the bicyclic pyrrolidine 
(1.113), followed by elaboration including oxidation, olefination and deprotections, 
kainic acid (1.1) was successfully made in 13% yield from (1.110) (scheme 1.35). 
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2. Results and Discussion 
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2.1 Introduction to This Project. 
The intention of this project was to follow the work of Greenwood and Murray:
47,48,53,57
 
1. To carry out and improve Greenwood’s synthesis of the oxazolidinone kainoid 
precursor (2.1).
47,48
 
2. To investigate further the diastereofacial selectivity of the oxazolidinone 
precursor (2.1) by carrying out 1,3-dipolar cycloadditions. 
3. To utilise the oxazolidinone precursor (2.1) to develop a novel synthetic route to 
kainic acid (1.1). 
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2.2 Introduction of Oxazolidinone (2.1). 
2.2.1 Formation of oxazolidinone precursor (2.1). 
The synthetic route to an important oxazolidinone precursor (2.1), originally developed 
by Greenwood is shown in scheme 2.1.
47,48
 
 
The carboxylic acid group of trans-4-hydroxy-L-proline (2.2) was converted to a methyl 
ester by Fischer esterification.
49
 The resulting hydrochloride salt (2.3) was protected with 
Boc (tert-butyl carbonate ester) to give Boc protected ester (2.4) in 96% yield over 2 
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steps. The protected amine (2.4) was then transferred to the mesylate (2.5) by treatment 
with mesyl chloride in 95% yield, then the mesyl group was replaced by a phenyl 
selenide with stereochemical inversion via SN2 mechanism,
50
 forming phenyl selenide 
(2.6) which was used without any purification. During this conversion, the methyl ester 
on the C-2 position was converted to an ethyl ester. Elimination, by conversion of the 
phenyl selenide (2.6) to its selenoxide with H2O2, gave alkene (2.7) in 65% yield over 2 
steps. The resultant ethyl ester (2.7) was reduced to an alcohol (2.8), and finally the 
alcohol (2.8) was cyclised to form a bicyclic oxazolidinone precursor (2.1) by the 
treatment with diethylamino sulfur trifluoride in 79% yield.
51
 
Some of the steps were improved by an alternative procedure in order to maximise the 
amount of oxazolidinone (2.1) capable of being prepared by this route. 
- Replacement of dioxane with DCM as the solvent for Boc protection of hydrochloride 
salt (2.3). 
Reasons: Better solubility for both reactant and product. 
Results: Yield has increased from 34% to 69% for my trial. 
- Eliminate mesylate (2.5) directly to alkene (2.7) with DBU, to avoid the selenation 
step. 
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Reasons: To simplify the synthesis of oxazolidinone (2.1), avoid the use of highly 
toxic organoselenium compound and increase the yield. 
Results: Mesylate (2.5) was successfully eliminated to an alkene directly in 
satisfactory yield (61%). However the stereo centre at C-2 of the resultant 
alkene was found to have racemised. 
- To reduce ester (2.7) to primary alcohol (2.8) with NaBH4 in the presence of 
methanol,
52
 instead of using DIBAL-H. 
Reasons: Increase the yield of the water soluble alcohol (2.8) by avoiding an aqueous 
work-up. 
Results: Yield has increased from 49% to 98% after purification. 
 
2.2.2 Diastereofacial selectivity of the oxazolidinone precursor (2.1). 
The diastereofacial selectivity of the oxazolidinone (2.1) was first discovered by 
Greenwood.
47,48
 A [2+2] photocycloaddition was performed by irradiating a solution of 
oxazolidinone (2.1) with dioxinone (2.9). Interestingly, the photolysis gave just one 
photoadduct (2.10), although only in 38% yield, together with isolated starting materials. 
This indicated the photocycloaddition occurred regio- and stereoselectively. The structure 
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of the cyclobutane (2.10) was defined by X-ray crystallographic analysis and surprisingly 
it showed the all-cis arrangement around the pyrrolidine ring, which indicated the 
dioxinone (2.9) had added onto the sterically hindered face of the oxazolidinone (2.1) 
(Scheme 2.2). 
 
Further investigations of the diastereofacial selectivity were carried by Greenwood, 
Murray
53
 and then later on by myself. 
Greenwood and Murray showed that this diastereofacial selectivity effect applied not 
only for [2+2] photocycloaddition. They treated a series of electrophiles with the 
oxazolidinone (2.1) (scheme 2.3).
53
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My investigation involved an intermolecular 1,3-dipolar cycloaddition, treating 
oxazolidinone (2.1) with a range of nitrile oxides as the electrophiles, to provide a series 
of isoxazolines.
54
 The nitrile oxides used in these cycloadditions were generated in situ 
by either -elimination of -chloro-oximes or dehydration of primary nitro compounds, 
both in the presence of Et3N (scheme 2.4). 
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Due to aldehydes being more commercially accessible than nitro compounds, most of the 
nitrile oxides used in this 1,3-dipolar cycloaddition were generated by the classical 
method (-elimination of -chloro-oximes).  
Condensation of aldehydes with hydroxylamine hydrochloride under basic conditions 
gave the corresponding aldoximes. These aldoximes were chlorinated to -chloro-oximes 
by the treatment with NCS in DCM (scheme 2.5).
55
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However, in many cases, -chloro-oximes are not sufficiently stable to isolate for use in 
the 1,3-dipolar cycloaddition, hence one pot synthesis of isoxazolines (developed by Lee) 
was employed,
56
 which involved the chlorination of aldoximes, -elimination of -
chloro-oximes and 1,3 dipolar cycloaddition. Addition of an 8% aqueous sodium 
hypochlorite solution to a solution of -chloro-oximes, Et3N and alkenes in benzene 
provided the corresponding isoxazolines in good yields. 
A series of isoxazolines (figure 2.1) was made by the treatment of oxazolidinone (2.1) 
with various nitrile oxides with different substituents (scheme 2.6). 
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Table I: 1,3-dipolar cycloadditions with nitrile oxides. 
Nitrile Oxides Alkene Isoxazolines Yield (%) 
(2.17a) (2.1) (2.17) 68 
(2.18a) (2.1) (2.18) 11 
(2.19a) (2.1) (2.19) 40 
(2.20a) (2.1) (2.20) 39 
(2.21a) (2.1) (2.21) 95 
(2.22a) (2.1) (2.22) 26 
(2.23a) (2.1) (2.23) 36 
(2.24a) (2.1) (2.24) 24 
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Although some of the isoxazolines were not obtained in good yield, interestingly, the X-
ray crystallographic analyses by Hitchcock showed all of the crystallisable isoxazolines 
(2.17), (2.20) and (2.21) were found to be cis at C-2, C-3 and C-4. Figure 2.2 showed the 
C-1 and O-1 of isoxazolines (2.17) and (2.20), C-7 and O-1 of (2.21) were located at the 
sterically hidden position of the corresponding isoxazolines. This showed that the 
corresponding 1,3-dipoles attacked on the sterically hidden concave face of 
oxazolidinone (2.1). In addition, no other stereo- and regio- isomers of (2.17), (2.20) and 
(2.21) were found by X-ray crystallographic analyses. 
 
(2.17)     (2.20) 
 
(2.21) 
Figure 2.2: X-ray crystallographic analyses of (2.17), (2.20) and (2.21) by Hitchcock 
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NMR analyses showed that the structure of rings A, B and C for all 1,3-dipolar 
cycloadducts (2.17-2.24) are very similar. The coupling constants for Ha-e are almost 
identical between each isoxazolines: for instance JHe ~ 2.4, 8.8 Hz, JHb ~ 8.1, 12.6 Hz, JHa 
~ 8.3 Hz and JHc ~ 4.3, 8.4 Hz (Figure 2.3). 
This indicated that only one isoxazoline isomer had been obtained, showing that these 
1,3-dipolar cycloadditions were occurring both regio- and stereoselectivity in each case. 
 
 
 
Figure 2.3 
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These results coincided with Greenwood and Murray’s explanation,48,53,58 that the 
diastereofacial selectivity was influenced by the distribution of electron density within 
the alkene (2.1).
53
 In our group, Viseux investigated this effect by molecular mechanics 
conformational searching and ab initio studies at the 6-31G* level, which show the 
preferred conformation (as calculated with MM+ set) of ozazolidinone (2.1) in Figure 2.4. 
 
Figure 2.4: 6-31G* representation of the HOMO of oxazolidinone (2.1).
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According to the investigation, Viseux suggested:
53
 
1. The lone pair electrons of the nitrogen in the oxazolidinone (2.1) is not in conjugation 
with the adjacent carbonyl group. This was supported by the observed IR stretch 
frequency of the C=O bond at 1751 cm
-1
, which is at the higher end of what would be 
expected for such a carbamate system. 
2. The HOMO shows the electron density of the unsymmetrical  system is higher on 
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the endo face of the oxazolidinone (2.1), thus leading to electrophiles approaching the 
concave face. 
Pyne has also reported the same phenomenon when dihydroxylating oxazolidinone (2.1) 
with osmium tetraoxide,
58
 and has rationalized that the pseudo-axial protons H-10 and H-
12 cause the exo face of oxazolidinone (2.1) to be sterically hidden from electrophilic 
attack (figure 2.5). 
 
 
Figure 2.5: Stereochemical model (Spartan AM1) of oxazolidinone (2.1).
58
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2.3 The Synthesis of Kainic Acid (1.1). 
2.3.1 Proposed Synthetic Route 
Utilising oxazolidinone (2.1) as a key precursor, a regio- and diastereoselective 1,3-
dipolar cycloaddition with ethyl nitrile oxide would give the tricyclic isoxazoline (2.20). 
Reducing (2.20) (by treatment with Raney Ni under H2 atmosphere) to the -hydroxy 
ketone (2.25), and subsequent elimination would lead to the enone (2.26). Performing a 
1,2-nucleophilic addition with trimethylsilyl-lithium followed by an acetylation would 
provide the acetate (2.27). After the Ireland Claisen rearrangement, the resulting silane 
would be eliminated to the desired C-2,C-3 trans, C-3,C-4 cis pyrrolidine (2.28) with 
fluoride. Final carbamate ring opening, oxidation and deprotection would yield kainic 
acid (1.1) (scheme 2.7). 
49 
 
 
2.3.2 1,3-dipolar cycloaddition of oxazolidinone (2.1) 
By carrying out Greenwood’s modified procedure for the preparation of oxazolidinone 
(2.1),
47,48
 we were able to subject the oxazolidinone (2.1) to the 1,3-dipolar cycloaddition 
conditions. Addition of triethylamine to a solution of oxazolidinone (2.1) and nitroethane 
in the presence of PhNCO or pTsCl gave just one isoxazoline (2.20) (Scheme 2.8). The 
structure of the resulting adduct was confirmed by X-ray crystallographic analysis 
(Figure 2.2). 
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In the first attempt, ethyl nitrile oxide (2.20a) was generated in situ by the Mukaiyama-
Hoshino procedure,
59
 dehydrating nitroethane with phenyl isocyanate in the presence of 
triethylamine. However, the diphenyl urea (2.29) by-product that precipitated from the 
1,3-dipolar cycloaddition solution was difficult to separate from the desired isoxazoline 
(2.20) due to their similar solubilities. Further purification by flash column 
chromatography still failed to separate them completely (Scheme 2.9). 
 
The second attempt employed a procedure reported by Shimizu,
60
 which involved 
generating nitrile oxides in situ by dehydration of the primary nitro compounds with aryl 
sulfonyl chlorides or ethyl chloroformate in the presence of triethylamine. 
51 
 
Addition of triethylamine to a solution of pTsCl, oxazolidinone (2.1) and nitroethane in 
benzene gave isoxazoline (2.20) in 39% yield. The by-products of this procedure (pTsOH 
and HCl) can be removed easily by an aqueous wash (Scheme 2.10). 
 
2.3.3 Ring-opening of isoxazoline (2.20) and formation of -unsaturated 
ketone (2.25) 
With the isoxazoline (2.20) in hand, we could now move forward to investigation of the 
ring-opening. 
Curran was the first to use Raney nickel to reduce isoxazolines into -hydroxy ketones 
in1983.
61
 The N-O bond of the isoxazoline ring was cleaved by hydrogenation with a 
Raney nickel catalyst in the presence of methanol and water, under acidic conditions 
(Scheme 2.11). 
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In the first attempt, I used phenyl substituted isoxazoline (2.17) as a study model to 
determine a suitable condition for this reduction. Acetic acid was used as the acid catalyst 
for this reductive ring-opening, without the use of any buffer, but no desired -hydroxy 
ketone (2.30) was obtained. The 
1
H NMR and M/z analyses showed that the isolated 
material was the saturated ketone (2.31) (Figure 2.6). 
 
Believing that the conditions used were too acidic for this ring-opening reduction, it was 
assumed that, whilst the desired -hydroxy ketone (2.30) has been formed, it then 
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eliminated to an enone (2.32) by an acid catalysed dehydration. However, when the 
enone (2.32) was exposed to a hydrogen atmosphere in the presence of Raney nickel, this 
led to an unwanted hydrogenation, giving the unexpected saturated ketone (2.31) 
(Scheme 2.12). 
In the second attempt, methyl substituted isoxazoline (2.20) was used for ring-opening 
reduction. Boric acid was used as the acid catalyst, in order to avoid the elimination 
taking place, and then desired -hydroxy ketone (2.25) was obtained smoothly as a green 
oil. 
The resultant -hydroxy ketone (2.25) was then eliminated to enone (2.26) by an acid 
catalysed dehydration. A catalytic amount of pTsOH was added to a mixture of (2.25) 
and toluene, followed by reflux for 2 hours. Water was collected by a Dean-Stark 
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apparatus and the enone (2.26) was obtained after the usual workup in 42% yield 
(Scheme 2.13). 
 
2.3.4 1,2-Nucleophilic addition of -unsaturated ketone (2.26) 
-Unsaturated ketone (2.26) was subjected to 1,2-nucleophilic addition conditions, to 
yield -silanol (2.33).62,63 Addition of TMSCH2Li to a solution of -unsaturated ketone 
(2.26) in THF at -78 
o
C formed -silanol (2.33) successfully. However, the desired 
adduct (2.33) was obtained in only 38% yield. 
Imamoto found that treatment of readily-enolisable enones such as (2.26) with organo-
lithium results primarily in the formation of enolates due to the strong basicity of the 
organolithium reagents.
64
 This author reported conversion of organolithium or Grignard 
reagents to the corresponding organocerium reagents with anhydrous cerium (III) 
chloride. These reacted cleanly with enolisable enones to provide the 1,2-nucleophilic 
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adducts in good to excellent yields (scheme 2.14).
64
 
 
By employing the organocerium procedure in the second attempt, the yield of -silanol 
(2.33) was significantly increased to 68% (scheme 2.15). 
NMR analysis showed that the chiral carbon adjacent to the hydroxyl group of -silanol 
(2.33) is racemic, this was supported by the appearance of an extra singlet peaks for both 
the TMS group (δ at 0.05) and its adjacent CH2 (δ at 1.13). 
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2.3.5 Formation of Ireland-Claisen rearrangement precursors (2.27) 
In order to carry out an Ireland-Claisen rearrangement for the formation of C-2,C-3 trans, 
C-3,C-4 cis pyrrolidine ring, the preparation of (2.27) was targeted. 
In the first attempt, acetic anhydride was selected to acetylate -silanol (2.33) in pyridine. 
However, it was found that the tertiary alcohol (2.33) was inert to this reagent, with TLC 
analysis showing no evidence for any reaction. 
In the second attempt, treatment of a solution of -silanol (2.33) in pyridine in the 
presence of DMAP with acetyl chloride, led to disappearance of starting material as 
indicated by TLC. Unfortunately, NMR and mass spectrometric analysis showed none of 
the desired acetate (2.27) had been formed (scheme 2.16). 
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Chan has found that acetylation of the -silylcarbinols with either acetyl chloride or 
thionyl chloride will gave a -silyl esters that will self-eliminate to an alkene by Peterson 
olefination (Scheme 2.17).
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Wei developed a new procedure for the Claisen rearrangement in 2007,
66
 involving 
Pd(II)-catalyzed vinyl ether exchange-Claisen rearrangement approach to give ,-
unsaturated aldehydes. Thus allylic alcohols could be converted to the corresponding ,-
unsaturated aldehydes under mild conditions, without using the toxic Hg(II) catalysts 
(Scheme 2.18). 
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We hoped that applying this procedure to the -silanol (2.33) would lead to the formation 
of aldehyde (2.34). However, as heating the mixture of -silanol (2.33) and a 
commercially available triethylene glycol divinyl ether (TGDV) in the presence of 1,10-
phenathroline Pd(OAc)2 complex (2.35) at 80 
o
C, TLC analysis showed no reaction had 
taken place, even when the temperature was increased to 130
 o
C (Scheme 2.19). 
 
2.3.6 1,4-nucleophilic addition of -unsaturated ketone (2.26) 
In an attempt to insert a functional group into the C-3 position of -unsaturated ketone 
(2.26), in order to form an pyrrolidine ring, a 1,4-nucleophilic addition was employed. 
Treatment of Gilman reagents (generated from an addition of organolithiums to a 
suspension of copper (I) bromide in THF in situ) with enone (2.26), led to the bicyclic 
pyrrolidines (2.36) and (2.37) being obtained (Scheme 2.20).
67
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The 1,4-nucleophilic additions proceeded in a diastereofacially selective manner, to give 
the pyrrolidines (2.36) and (2.37) with only the C-2,C-3 trans, C-3,C-4 trans 
configuration (scheme 2.21), as supported by Day’s NMR analyses. 
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The 
1
H NMR of (2.37) showed that JHc-Hb = 3.5 Hz, which is smaller compared to JHk-Hb 
= 7.8 Hz, this showed that Hc is attached to the concave face of the bicyclic pyrrolidine 
(2.37) and Hk is almost eclipsed with Hb. 
ROESY experiments showed that Hf and Hc are closer in space than Hf and Hk, and also 
no correlation between Hb and Hf, which indicated Hf is attached to the sterically hidden 
concave face of (2.37). No correlation was observed between Ha and Hc, however Ha was 
correlated with Hg, which showed that Ha and the butyl group are likely attached to the 
same face of the bicyclic pyrrolidine (2.37) (figure 2.7). 
 
The 
1
H NMR of (2.36) also showed that JHc-Hb = 2.5 Hz is smaller than JHj-Hb = 7.6 Hz, 
hence Hc is attached to the concave face of (2.36) and Hj is cis related to Hb. 
ROESY experiments showed that Hf and Hc are closer in space compared to Hf and Hj, 
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also only weak correlation was observed between Hg and Hc, this indicated the phenyl 
group of (2.36) is cis related to Hb. No correlation was observed between He and Hg, 
however the spectrum showed that Ha and Hg, He and Hc are close in space, which 
showed that the ketone group was attached to the concave face of (2.36) (figure 2.8). 
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By modifying this procedure, we hoped that the C-2,C-3 trans, C-3,C-4 cis kainic acid 
framework (2.38) would be generated by treating the -unsaturated ketone (2.26) with 
copper (I) dimethyl malonate (2.39) followed by a thermal decarboxylation (Scheme 
2.22).
68
 
 
If it proved possible to achieve the kainic acid framework (2.38), olefination of the 
ketone, ring-opening of the carbamate, oxidation and deprotection would led to kainic 
acid (1.1) in 14 steps from trans-4-hydroxy-L-proline (2.2). 
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2.4 Conclusion 
The formation of oxazolidinone precursor (2.1) has been achieved by repeating the 
literature apposed of Greenwood. Some of the steps were improved by using alternative 
procedures or reagents in order to increase the amount of oxazolidinone (2.1) obtained.  
Various nitrile oxides were utilised as the electrophiles, to investigate the diastereofacial 
selectivity of oxazolidinone precursor (2.1) by carrying out a series of 1,3 dipolar 
cycloadditions. The results coincided with previous investigations;
48,53,57
 the stereo 
configurations of C-2, C-3 and C-4 being cis related for all isoxazolines, which 
demonstrated that the electrophiles favoured approach to the concave face of the 
oxazolidinone (2.1). 
The formation of -silanol (2.33) was successfully achieved, although the conversion of 
(2.33) to the Ireland-Claisen rearrangement precursor (2.27) was not successful.  
In addition, the diastereofacially selective 1,4-nucleophilic addition to enone (2.26) was 
also attempted. However, only sterically unfavoured C-2,C-3 trans, C-3,C-4 trans 
configured (2.36) and (2.37) were obtained.  
If it proved possible to achieve the sterically favoured kainic acid framework (2.38), a 
further 4-step elaboration would lead the formation of (-)--kainic Acid (1.1).  
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3. Experimental Section 
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3.1 General Experimental Procedures 
All reactions were conducted under a nitrogen atmosphere, using oven dried glassware. 
Reactions requiring anhydrous conditions were carried out under a nitrogen atmosphere 
using flame-dried glassware. 
Purification by flash column chromatography was performed using Merk Kieselgel 60 
silica gel (particle size less than 0.063 nm) eluting with the stated solvents purchased 
from Fisher scientific. Thin layer chromatography analyses were performed using Merk 
glass backed plates precoated with a 0.25 mm layer of 60 F254 silica gel. Visualization of 
the TLC plates was under ultra violet radiation (254 nm) and by potassium permanganate 
or vanillin dip. 
Melting points were recorded using a Gallenkamp melting point apparatus without 
correction. 
1H NMR spectra were recorded on a Bruker Advance AC-300 instrument at 300 MHz or 
a Bruker AMX 500 at 500 MHz. Samples were run in deuterochloroform or 
deuteromethanol at ambient temperature and were referenced to deuterochloroform or 
deuteromethanol internal standard. Chemical shifts are quoted in ppm on the  scale and 
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coupling constants J are measured in Hz. The following abbreviations were used to 
describe multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet 
of doublets; ddd, doublet of doublet of doublets; dddd, doublet of doublet of doublet of 
doublets; dt, doublet of triplets. 
13C NMR spectra were recorded on a Bruker Advance AC-300 instrument at 75 MHz or 
a Bruker AMX 500 instrument at 125 MHz. Samples were run in deuterochloroform or 
deuteromethanol at ambient temperature and are referenced to deuterochloroform or 
deuteromethanol internal standard. Chemical shifts are quoted in ppm on the  scale. 
Infrared spectra were recorded on Perkin-Elmer Spectrum One Fourier transform 
spectrometer, with a universal ATR sampling accessory, with max measured in cm
-1
. 
Low resolution and high resolution mass spectra were recorded on a Fisons Instrument 
VG Autospec mass spectrometer. The following abbreviations were used to represent the 
experiment: EI - electron impact, ESI - electron spray ionization, HRMS - high resolution 
mass spectrometry, LRMS - low resolution mass spectrometry. 
Specific rotations were measured on a BS ADP 440 polarimeter at ambient temperature 
and 589 nm. 
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All organic solvents were distilled under a nitrogen atmosphere from an appropriate 
drying agent, see below. 
Solvent Drying Reagent 
Acetonitrile Calcium hydride 
Benzene Calcium hydride 
Diethyl ether Sodium in the presence of 
benzophenone 
Dichloromethane Calcium hydride 
Ethanol Magnesium turnings
*
 
Methanol Magnesium turnings
*
 
Pyridine Calcium hydride 
Tetrahydrofuran Sodium in the presence of 
benzophenone 
*
Magnesium turnings were activated by heating with a crystal of I2 under a 
nitrogen atmosphere. 
All compounds in the experimental detail section are numbered to aid identification of 
protons and carbons in the relevant spectra. This numbering may not always correspond 
with that of the I.U.P.A.C. guidelines.  
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3.2 Experimental Detail. 
3.2.1 Methyl (4R)-4-hydroxy-L-prolinate hydrochloride (2.3) 
 
The title compound was prepared by a modification of the procedure of Greenwood.
47,48 
A suspension of trans-4-hydroxy-L-proline (2.2) (10.0 g, 76.0 mmol) in methanol (40 mL) 
was stirred and cooled to 0
o
C. Thionyl chloride (2.49 mL, 34.31 mmol) was added to the 
reaction mixture dropwise at 0 
o
C. The reaction mixture was stirred at 0 
o
C for 1 hour 
before heated to reflux for 24 hours, then being allowed to re-cool to 0 
o
C. Diethyl ether 
(80 mL) added, the white precipitate was filtered, washed with diethyl ether (2 x 20 mL) 
and dried under reduced pressure to give methyl (4R)-4-hydroxy-L-prolinate 
hydrochloride (2.3) as a white solid (11.288 g). 
Spectroscopic data identical to literature values.
47,48
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3.2.2 1-tert-butyl 2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate (2.4) 
 
The title compound was prepared by a modification of the procedure of Greenwood.
47,48 
Diisopropylethylamine (23.86 mL, 136.56 mmol) and di-tert-butyl dicarbonate (14.9 g, 
68.28 mmol) were added to a suspension of methyl (4R)-4-hydroxy-L-prolinate 
hydrochloride (2.3) (11.288 g) in DCM (80 mL) at 0
o
C. The reaction mixture was stirred 
and allowed to warm to room temperature for 24 hours before being concentrated under 
reduced pressure. The residue was diluted with ethyl acetate (50 mL), then washed with 
1M citric acid solution (50 mL). The aqueous phase was further extracted with ethyl 
acetate (3 x 100mL). The organic phases were combined then washed with saturated 
sodium hydrogen carbonate solution (300 mL) and brine (300 mL), dried over 
magnesium sulfate and concentrated in vacuo to give 1-tert-butyl 2-methyl (2S,4R)-4-
hydroxypyrrolidine-1,2-dicarboxylate (2.4) as a yellow oil. No further purification was 
required. Overall yield for experiments 3.2.1 and 3.2.2 (9.063 g, 48 %). 
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1
H NMR (300MHz, CDCl3) δ: 1.38 and 1.43 (2 x s, 9H, g), 2.03 (ddd, 1H, J = 12.6, 8.3, 
4.3 Hz, b), 2.27 (dd, 1H, J = 12.2, 20.0 Hz, a), 2.79 (brs, 1H, 
c), 3.63-3.41 (m, 2H, e, f), 3.71 (s, 3H, h), 4.41 – 4.35 (m, 1H, 
i), 4.46 -4.45 (m, 1H, d). 
13
C NMR (75.5MHz, CDCl3) δ: 28.2 and 28.3 (7), 38.4 and 39.0 (1), 52.0 (8), 54.6 (3), 
57.4 and 57.9 (4), 69.3, 70.0 (2), 80.3 and 80.4 (6), 154.0 
(5), 173.6 (9). 
Spectroscopic data identical to literature values.
47,48
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3.2.3 1-tert-butyl 2-methyl (2S,4R)-4-(methylsulfonyloxy)pyrrolidine-1,2-dicarboxylate 
(2.5) 
 
The title compound was prepared by a modification of the procedure of Greenwood.
47,48 
Methanesulfonyl chloride (21.560 g, 188.22 mmol) and 4-dimethylaminopyridine (2.09 g, 
17.111 mmol) were added to a stirred solution of 1-tert-butyl 2-methyl (2S,4R)-4-
hydroxypyrrolidine-1,2-dicarboxylate (2.4) (41.922 g, 171.11 mmol) and triethylamine 
(25.71 mL, 184.80 mmol) in dichloromethane (600 mL) at 0
o
C. The reaction mixture was 
stirred and allowed to warm to room temperature for 15 hours before cooling to 0
o
C and 
adding water (300 mL). The phases were separated and the aqueous phase was extracted 
with dichloromethane (3 x 200 mL). The organic extracts were combined and washed 
with 1M citric acid solution, saturated sodium hydrogen carbonate solution and dried 
over magnesium sulfate. The extract was concentrated under reduced pressure and the 
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crude product was purified by flash column chromatography on silica gel, eluting with 50 
% ethyl acetate / petrol to give 1-tert-butyl 2-methyl (2S,4R)-4-
[(methylsulfonyl)oxy]pyrrolidine-1,2-dicarboxylate (2.5) as a white solid (45.213 g, 82 
%). 
1
H NMR (300MHz, CDCl3) δ: 1.44 and 1.40 (2 x s, 9H, g), 2.28 -2.19 (m, 1H, b), 2.68 - 
2.52 (m, 1H, a), 3.04 (s, 3H, c), 3.73 (s, 3H, h), 3.86 – 
3.67 (m, 2H, e, f), 4.47 – 4.35 (m, 1H, i), 5.24 (m, 1H, d). 
13
C NMR (75.5MHz, CDCl3) δ: 28.1 and 28.3 (7), 36.2 and 37.4 (1), 38.6 and 38.7 (10), 
52.1 and 52.4 (3), 52.3 and 52.5 (8), 57.0 and 57.4 (4), 
78.1 and 77.9 (2), 80.9 (6), 153.3 and 153.8 (5), 172.5 and 
172.7 (9). 
Spectroscopic data identical to literature values.
47,48
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3.2.4 1-tert-butyl 2-ethyl (2S,4S)-4-(phenylseleno)pyrrolidine-1,2-dicarboxylate (2.6) 
 
The title compound was prepared by a modification of the procedure of Greenwood.
47,48
 
Sodium borohydride (6.349 g, 167.84 mmol) was added to a stirred suspension of 
diphenyl diselenide (26.922 g, 76.93 mmol) in anhydrous ethanol (750 mL) at 0
o
C 
portionwise. The reaction mixture was allowed to warm to room temperature and stirred 
for 1 hour before re-cooling to 0
o
C. The solution of 1-tert-butyl 2-methyl (2S,4R)-4-
(methylsulfonyloxy)pyrrolidine-1,2-dicarboxylate (2.5) (45.213 g, 139.87mmol) in 
anhydrous ethanol (250mL) was added to the reaction mixture followed by heating under 
reflux for 24 hours. The reaction mixture was contracted under reduced pressure, re-
diluted with diethyl ether (1000 mL) and washed with water (600 mL). The phases were 
separated and the aqueous phase was extracted with diethyl ether (3 x 500 mL). The 
organic phases were combined and further washed with saturated sodium chloride 
solution (600 mL), dried over magnesium sulfate then concentrated in vacuo to give the 
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crude 1-tert-butyl 2-ethyl (2S,4S)-4-(phenylseleno)pyrrolidine-1,2-dicarboxylate (2.6) as 
a brown oil (55.50 g). 
 
3.2.5 1-tert-butyl 2-ethyl (2S)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (2.7) 
 
The title compound was prepared by a modification of the procedure of Greenwood.
47,48 
Hydrogen peroxide solution (35 wt. %, 74.53 mL, 766.44 mmol) was added to a 
vigorously stirred solution of crude 1-tert-butyl 2-ethyl (2S,4S)-4-(phenylseleno) 
pyrrolidine-1,2-dicarboxylate (2.6) (55.50 g) and pyridine (24.26 mL, 64.57 mmol) in 
dichloromethane (1000 mL) dropwise over 30 minutes at -78
o
C. The reaction mixture 
was stirred and allowed slowly to warm to room temperature for 18 hours. After adding 
saturated ammonium chloride solution (500 mL), the phases were separated and the 
aqueous phase extracted with dichloromethane (3 x 250 mL). The organic phases were 
combined, washed with saturated ammonium chloride solution (500 mL) and saturated 
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sodium chloride solution (500 mL), dried over magnesium sulfate and concentrated in 
vacuo. The residue was purified by flash column chromatography on silica gel, eluting 
with 20 % diethyl ether / petrol, then 50 % diethyl ether / petrol to give 1-tert-butyl 2-
ethyl (2S)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (2.7) as a brown oil (19.841 g, 59 
%). 
1
H NMR (300MHz, CDCl3) δ: 1.21 - 1.28 (m, 3H, c), 1.41 and 1.46 (2 x s, 9H, g), 4.10 - 
4.30 (m, 4H, d,e,f), 4.90 - 5.01 (m, 1H, h), 5.68 - 5.75 (m, 
1H, a), 5.90 - 5.98 (m, 1H, b). 
13
C NMR (75.5MHz, CDCl3) δ: 14.1 and 14.2 (10), 28.2 and 28.3 (7), 53.2 and 53.5 (3), 
66.1 (8), 66.3 and 66.6 (4), 80.0 and 80.1 (6), 124.7 and 
124.8 (2), 129.1 and 129.2 (1), 153.4 and 153.8 (5), 170.2 
and 170.6 (9). 
Spectroscopic data identical to literature values.
47,48
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3.2.6 tert-butyl (2S)-2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (2.8) 
 
Sodium borohydride (376 mg, 9.948 mmol) was added to a stirred solution of 1-tert-butyl 
2-ethyl (2S)-2,5-dihydro-1H-pyrrole-1,2-dicarboxylate (2.7) (400 mg, 1.658 mmol) in 
tetrahydrofuran (20 mL). The reaction mixture was heated to 65
o
C for 15 min before 
adding methanol (4 mL) dropwise over 15 min and the reaction was then heated under 
reflux for 2 hr before cooling to room temperature. The reaction mixture was then 
concentrated in vacuo and the residue was purified by flash column chromatography on 
77 
 
silica gel, eluting with neat ether to give tert-butyl (2S)-2-(hydroxymethyl)-2,5-dihydro-
1H-pyrrole-1-carboxylate (2.8) as a yellow oil (305 mg, 92 %). 
1
H NMR (300MHz, CDCl3) δ: 1.49 (s, 9H, g), 3.57 (t, 1H, J = 8.1, f), 3.78 (t, 1H, J = 9.7 
Hz, e), 4.08 (m, 1H, d), 4.18 (d, 1H, J = 14.4 Hz, c), 4.59 
(s, 1H, i), 4.74 (s, 1H, h), 5.65 (d, 1H, J = 8.6 Hz, a), 5.67 
(m, 1H, b). 
13
C NMR (75.5MHz, CDCl3) δ: 28.4 (7), 54.1 (8), 67.1 (3), 67.5 (4), 80.5 (6), 126.6 (1), 
126.7 (2), 156.4 (5). 
Spectroscopic data identical to literature values.
47,48
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3.2.7 (S)-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) 
 
The title compound was prepared by a modification of the procedure of Greenwood.
47,48 
Diethylamino sulfur trifluoride (2.83mL, 12.05 mmol) was added to a stirred solution of 
tert-butyl (2S)-2-(hydroxymethyl)-2,5-dihydro-1H-pyrrole-1-carboxylate (2.8) (1.847 g, 
9.27 mmol) in dichloromethane (60 mL) at 0
o
C. The reaction mixture was allowed to 
warm to room temperature and stirred for 16 hours, then re-cooled to 0
o
C before adding 
water (50 mL). The phases were separated, the aqueous phase was extracted with 
dichloromethane (3 x 100 mL), the organic phases were combined, washed with saturated 
sodium chloride solution (100 mL), dried over magnesium sulfate and concentrated in 
vacuo.  The residue was purified by flash column chromatography on silica gel, eluting 
with 70 % diethyl ether / petrol to give (S)-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-
one (2.1) as a yellow oil (0.958 g, 83 %). 
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1
H NMR (300MHz, CDCl3) δ: 3.76 - 3.82 (m, 1H, d), 4.23 (dd, 1H, J = 5.1, 8.6c Hz, c), 
4.40 - 4.33 (m, 1H, d), 4.59 (d, 1H, J = 8.6c Hz, c), 4.76 – 
4.66 (m, 1H, e), 5.88 - 5.90 (m, 1H, a), 6.02 – 6.04 (m, 1H, b). 
13
C NMR (75.5MHz, CDCl3) δ: 54.8 (3), 64.6 (5), 68.7 (4), 128.9 (1), 130.8 (2), 163.3 (6). 
Spectroscopic data identical to literature values.
47,48
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3.2.8 benzaldehyde oxime 
 
The title compound was prepared by a modification of the procedure of Liu.
55
  
A solution of sodium carbonate (6.0 g, 56.6 mmol) in water (50mL) was added to a 
stirred solution of hydroxylamine hydrochloride (7.87 g, 113.00 mmol) and benzaldehyde 
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(10.00 g, 94.3 mmol) in water (50 mL) dropwise at 0
o
C, the reaction mixture was allowed 
to warm to room temperature for 2 hours, followed by extraction with ether (3 x 100 mL). 
The organic phases were combined, washed with water (200 mL), dried over magnesium 
sulfate and concentrated in vacuo and the crude product was purified by fractional 
distillation to give benzaldehyde oxime as a white solid (10.959 g, 96 %). 
1
H NMR (300MHz, CDCl3) δ: 3.42 (d, 1H, J = 7.03 Hz, e), 7.24 - 7.98 (m, 4H, a,b), 8.1 
(m, 1H, c), 9.17 (s, 1H, d). 
13
C NMR (75.5MHz, CDCl3) δ: 128.0 (2), 129.3 (3), 130.3 (4), 130.7 (1), 145.5 (5). 
FTIR max cm
-1
: 1679, 2558, 2842 
LRMS (ES+): 122 ([MH]
+
) 
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3.2.9 N-hydroxybenzenecarboximidoyl chloride 
 
The title compound was prepared by a modification of the procedure of Liu.
55 
N-chlorosuccinimide (21.282 g, 136.9 mmol) was added to a stirred solution of 
benzaldehyde oxime (13.800 g, 114.0 mmol) in dichloromethane (150 mL). The reaction 
mixture was allowed to stir for 15 hours before being poured into ice water (600 mL). 
The organic phase was washed with water (3 x 50 mL), dried over magnesium sulfate and 
concentrated in vacuo to give the crude N-hydroxybenzenecarboximidoyl chloride as a 
white solid (14.610 g, 82 %) that was used for the next reaction without any purification. 
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3.2.10 (3aS,8aR,8bR)-3-phenyl-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5]pyrrolo[3, 
4-d]isoxazol-6-one (2.17) 
 
N-hydroxybenzenecarboximidoyl chloride (2.0 g, 10.0 mmol), (S)-5,7a-dihydro-1H-
pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (1.256 g, 10.0 mmol) was dissolved in benzene (25 
mL). To this stirring solution, triethylamine (1.212 g, 12.0 mmol) was added dropwise 
before stirring for 18 hours. The white solid was filtered, rinsed with cold ether (30 mL) 
and recrystallised from dichloromethane to give (3aS,8aR,8bR)-3-phenyl-3a,8,8a,8b-
tetrahydro-4H-[1,3]oxazolo[3',4':1,5]pyrrolo[3,4-d]isoxazol-6-one (2.17) as colourless 
crystals (1.633 g, 68 %). 
Melting range: 225.2 – 226.3 oC 
[α]  
  
= -197 (c= 0.60, MeOH) 
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1
H NMR (300MHz, CD3OD) δ: 3.66 (dd, 1H, J = 8.2, 12.7c Hz, c) , 4.25 (dd, 1H, J = 1.8, 
12.7c Hz, c) , 4.41 (m, 1H, b) , 4.55 (td, 1H, J = 2.1, 8.5a 
Hz, e) , 4.73 (t, 1H, J = 8.5e Hz, a) , 4.94 (dd, 1H, J = 2.5, 
8.7d Hz, d) , 5.54 (dd, 1H, J = 4.3, 8.7d Hz, d) , 7.56 (d,1H, 
J = 1.9g Hz, h) 7.69 (d, 2H, J = 1.9g Hz, f), 7.75 - 7.78 (tt, 
2H, J = 1.9f, 5.2 Hz, g). 
13
C NMR (75.5MHz, CD3OD) δ: 49.9 (3), 55.0 (2), 63.1 (6), 64.9 (5), 85.9 (7), 127.5 (9), 
129.4 (10), 131.0 (8), 131.2 (11), 147.6 (1), 157.3 (4). 
FTIR max cm
-1
: 1745 (s), 2974 (s) 
HRMS (ESI): calcd. for C13H12N2O3 [M+Na]
+
 267.0745 found 267.0735 
 
 
84 
 
3.2.11 heptanal oxime 
 
The title compound was prepared by a modification of the procedure of Liu.
55 
A solution of sodium carbonate (3.250 g, 30.65 mmol) in water (20mL) was added to a 
stirred solution of hydroxylamine hydrochloride (3.80 g, 54.73 mol) and heptanal (5.0 g, 
43.79 mmol) in water (30 mL) added dropwise at 0
o
C. The reaction mixture was allowed 
to warm to room temperature for 2 hours, followed by extraction with ether (3 x 100 mL). 
The organic phases were combined, washed with water (200 mL), dried over magnesium 
sulfate and concentrated in vacuo, to give the crude heptanal oxime as a white solid (5.48 
g, 97 %). 
Melting range: 44.7 - 46.0
o
C. 
1
H NMR (300MHz, CDCl3) δ: 0.86 (td, 3H, J = 2.3, 6.7 Hz, e), 1.23-1.35 (m, 6H, f), 1.46 
(m, 2H, d), 2.17 (q, 1H, J = 7.2c Hz, c), 2.35 (q, 1H, J = 7.2c, 
c), 7.39 (t, 1H, J = 6.2 Hz, b), 9.65 (s, 1H, a). 
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13
C NMR (75.5MHz, CDCl3) δ: 13.8 (7), 22.4 (6), 26.5 (3), 28.9 (4), 29.3 (2), 31.4 (5), 
152.0 (1). 
FTIR max cm
-1
: 1666, 2924 
HRMS (ESI): calcd. for C7H15NO [M+Na]
+
 152.1051 found 152.1037 
 
 
3.2.12 (3aS,8aR,8bR)-3-hexyl-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5]pyrrolo[3, 
4-d]isoxazol-6-one (2.18) 
 
To a stirred solution of (S)-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (100 
mg, 0.800 mmol), heptanal oxime (100.3 mg, 0.879 mmol) and triethylamine (0.134 mL, 
0.960 mmol) in dichloromethane (20 mL), 8 % aqueous sodium hypochlorite (10 mL, 
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12.3 mmol) was added dropwise over 15 min at 0
o
C, then the reaction mixture was 
allowed to stir for 12 hour. The aqueous phase was separated before extraction with 
dichloromethane (3 x 50 mL), the organic phases were combined and washed with water 
(2 x 50 mL), then dried over magnesium sulfate and concentrated in vacuo. Diethyl ether 
(30 mL) was added to the residue and then filtered, the solid residue was rinsed with 
diethyl ether (30 mL) and then recrystallised from methanol give (3aS,8aR,8bR)-3-hexyl-
3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5] pyrrolo[3,4-d] isoxazol-6-one (2.18) as a 
white solid (23 mg, 11 %). 
Melting range: 139.9 – 141.5oC. 
[α]  
  
= -81.0 (c= 0.58, CHCl3) 
1
H NMR (500MHz, CDCl3) δ: 0.87 (t, 3H, J = 5.8i Hz, f), 1.29 (m, 4H, j), 1.34 (m, 2H, i), 
1.53 (m, 1H, h), 1.61 (m, 1H, h), 2.25 (m, 1H, g), 2.44 (m, 
1H, g), 3.25 (dd, 1H, J = 7.9a, 12.8b Hz, b), 3.85 (t, 1H, J = 
7.9b Hz, a), 3.99 (d, 1H, J = 12.8b Hz, b), 4.05 (m, 1H, d), 
4.46 (t, 1H, J = 8.6e Hz, e), 4.64 (dd, 1H, J = 2.2, 8.6e Hz, e), 
5.02 (dd, 1H, J = 4.7, 8.3 Hz, c). 
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13
C NMR (125.7MHz, CDCl3) δ: 13.9 (13), 22.4 (12), 25.9 (9), 26.0 (10), 28.8 (11), 31.3 
(8), 48.1 (6), 56.8 (1), 62.7 (3), 64.2 (4), 83.4 (2), 158.8 
(7), 160.8 (5). 
FTIR max cm
-1
: 1724, 2932  
HRMS (ESI): calcd. for C13H20N2O3 [M+Na]
+
 275.1371 found 275.1358 
 
3.2.13 octanal oxime 
 
The title compound was prepared by a modification of the procedure of Liu.
55 
A solution of sodium carbonate (2.00 g, 18.88 mmol) in water (20mL) was added to a 
stirring solution of hydroxylamine hydrochloride (2.343 g, 33.71 mol) and octanal (3.457 
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g, 26.97 mmol) in water (30 mL) dropwise at 0
o
C. Then the reaction mixture was then 
allowed to warm to room temperature for 2 hours, followed by extraction with ether (3 x 
100 mL). The organic phases were combined, washed with water (200 mL), dried over 
magnesium sulfate and concentrated in vacuo. No purification was required to give 
octanal oxime as a white solid (2.322 g, 60 %). 
Melting range: 52.2 - 52.8
o
C. 
1
H NMR (300MHz, CDCl3) δ: 0.86 (td, 3H, J = 2.3, 6.7 Hz, e), 1.21-1.37 (m, 8H, d), 1.45 
(m, 2H, c), 2.18 (q, 1H, J = 7.1b Hz, b), 2.37 (q, 1H, J = 
7.1b, b), 7.37 (t, 1H, J = 6.2 Hz, f), 9.65 (s, 1H, a). 
13
C NMR (75.5MHz, CDCl3) δ: 13.9 (8), 22.4 (7), 25.9 (2), 26.5 (3), 28.9 (4), 29.3 (5), 
31.4 (6), 152.1 (1). 
FTIR max cm
-1
: 1667, 2919 
HRMS (ESI): calcd. for C8H17NO [M+Na]
+
 166.1280 found 166.1268 
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3.2.14 (3aS,8aR,8bR)-3-heptyl-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5]pyrrolo[3, 
4-d]isoxazol-6-one (2.19) 
 
To a stirred solution of (S)-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (100 
mg, 0.800 mmol), octanal oxime (127 mg, 0.879 mmol) and triethylamine (0.134 mL, 
0.960 mmol) in dichloromethane (20 mL), 8 % aqueous sodium hypochlorite (10 mL, 
12.3 mmol) was added dropwise over 15 min at 0
o
C. The reaction mixture was allowed to 
stir for 12 hours, the aqueous phase was separated before extraction with 
dichloromethane (3 x 50 mL). The organic phases were combined and washed with water 
(2 x 50 mL), then dried over magnesium sulfate and concentrated in vacuo. Diethyl ether 
(30 mL) was added to the residue and then filtered, the solid residue was rinsed with 
diethyl ether (30 mL) and then recrystallised from methanol give (3aS,8aR,8bR)-3-heptyl-
3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5] pyrrolo[3,4-d] isoxazol-6-one (2.19) as a 
white solid (85 mg, 40 %). 
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Melting range: 141.8 - 145.7
o
C. 
[α]  
  
= -96.8 (c= 0.25, CHCl3) 
1
H NMR (500MHz, CDCl3) δ: 0.86 (t, 3H, J = 6.6 Hz, k), 1.28 (m, 4H, f, i), 1.39 (t, 4H, J 
= 7.3 Hz, j), 1.54 (m, 1H, h), 1.61 (m, 1H, h), 2.25 (m, 1H, 
g), 2.44 (m, 1H, g), 3.25 (dd, 1H, J = 7.8a, 12.8b Hz, b), 3.85 
(t, 1H, J = 7.8b Hz, a), 3.99 (d, 1H, J = 12.8b Hz, b), 4.06 (m, 
1H, d), 4.46 (t, 1H, J = 8.7e Hz, e), 4.65 (dd, 1H, J = 2.2, 
8.7e Hz, e), 5.02 (dd, 1H, J = 4.7, 8.5 Hz, c). 
13
C NMR (125.7MHz, CDCl3) δ: 14.0 (14), 22.5 (13), 26.0 (9), 28.8 (11), 29.1 (10), 31.6 
(12), 45.9 (8), 48.1 (6), 56.8 (1), 62.7 (3), 64.2 (4), 83.4 
(2), 158.7 (7), 160.7 (5). 
FTIR max cm
-1
: 1725, 2930 
HRMS (ESI): calcd. for C14H22N2O3 [M+Na]
+
 289.1528 found 289.1513 
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3.2.15 ethyl (3aS,8aR,8bR)-6-oxo-3a,8,8a,8b-tetrahydro-4H[1,3]oxazolo[3',4':1,5]pyrrolo 
[3,4-d]isoxazole-3-carboxylate (2.20) 
 
Triethylamine (484 mg, 4.795 mmol) was added to a stirred solution of (S)-5,7a-dihydro-
1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (300 mg, 2.398 mmol), nitroethane (216 mg, 
2.877 mmol) and p-toluenesulfonyl chloride (913 mg, 4.795 mmol) in benzene (25 mL) 
at 0
 o
C. The reaction mixture was allowed to warm room temperature for 12 hours before 
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washing with water (3 x 50 mL). The organic phase was dried over magnesium sulfate, 
and concentrated in vacuo. The residue was purified by flash column chromatography on 
silica gel, eluting with 9:1 diethyl ether/petrol then neat ethyl acetate to give ethyl 
(3aS,8aR,8bR)-6-oxo-3a,8,8a,8b-tetrahydro-4H[1,3]oxazolo[3',4':1,5]pyrrolo[3,4-d] 
isoxazole-3-carboxylate (2.20) as colourless crystals (170 mg, 39 %). 
Melting range: 123.6 - 126.4
o
C. 
[α]  
  
= -150.3 (c= 0.93, MeOH) 
1
H NMR (300MHz, CDCl3) δ: 2.01 (s, 3H, f), 3.26 (dd, 1H, J = 7.5a, 13.1b Hz, b), 3.83 (t, 
1H, J = 7.5b Hz, a), 4.02 (d, 1H, J = 13.1b Hz, b), 4.06 (m, 
1H, d), 4.47 (td, 1H, J = 3.4, 8.7e Hz, e), 4.66 (dd, 1H, J = 
3.0, 8.7e Hz, e), 5.05 (m, 1H, c). 
13
C NMR (75.5MHz, CDCl3) δ: 11.3 (8), 48.0 (4), 58.0 (1), 62.7 (3), 64.3 (6), 84.7 (2), 
155.2 (7), 176.9 (5). 
FTIR max cm
-1
: 1732(s), 2964 (s) 
HRMS (ESI): calcd. for C8H10N2O3 [M+Na]
+
 205.0589 found 205.0581 
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3.2.16 1-(nitromethyl)cyclohexene 
 
In a round-bottomed flask fitted with a Dean and Stark trap was placed a solution of 
cyclohexanone (3.0 g, 30.57 mmol), N,N dimethylethylenediamine (1.776 g, 15.29 mmol) 
and nitromethane (7.463 g, 122.2 mmol) in benzene (75 mL). The solution was heated 
under reflux for 18 hours, then cooled, washed with 2M hydrochloric acid (20 mL) and 
water (20 mL), dried over magnesium sulfate, and concentrated in vacuo.  The residue 
was purified by flash column chromatography on silica gel, eluting with 20 % diethyl 
ether / petrol give 1-(nitromethyl)cyclohexene as a yellow oil (301 mg, 7 %). 
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1
H NMR (300MHz, CDCl3) δ: 1.57 – 1.68 (m, 4H, c, d) , 2.08 (m, 4H, b, e) , 4.78 (s, 2H, 
a), 5.92 (s, 1H, f). 
13
C NMR (75.5MHz, CDCl3) δ: 21.4 (6), 22.1 (5), 25.3 (7), 26.5 (4), 82.8 (1), 128.5 (3), 
133.1 (2). 
Spectroscopic data identical to literature values.
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3.2.17 (3aS,8aR,8bR)-3-cyclohex-1-en-1-yl-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4': 
1,5]pyrrolo[3,4-d]isoxazol-6-one (2.21) 
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Triethylamine (221 mg, 2.192 mmol) was added to a stirred solution of (S)-5,7a-dihydro-
1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (137 mg, 1.096 mmol), 1-(nitromethyl) 
cyclohexene (170 mg, 1.206 mmol) and p-toluenesulfonyl chloride (418 mg, 2.192 mmol) 
in chloroform (25 mL) at 0
 o
C. The reaction mixture was allowed to warm room 
temperature for 15 hours before being washed with water (3 x 50 mL). The organic phase 
was dried over magnesium sulfate, and concentrated in vacuo. The residue was purified 
by flash column chromatography on silica gel, eluting with 7:1 diethyl ether / petrol give 
(3aS,8aR,8bR)-3-cyclohex-1-en-1-yl-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5] 
pyrrolo[3,4-d]isoxazol-6-one (2.21) as colourless crystals (284 mg, 95 %). 
Melting range: 228.4 - 231.5
o
C.  
[α]  
  
= -288.4 (c= 0.95, MeOH) 
1
H NMR (300MHz, CDCl3) δ: 1.59 (m, 4H, h, j), 2.20 (m, 4H, g, i), 3.31 (dd, 1H, J = 8.3, 
12.5c Hz, c), 3.93 (dd, 1H, J = 2.0a, 12.5c Hz, c) 4.00 (td, 1H, 
J = 2.0c, 8.5b Hz, a), 4.09 (m, 1H, d), 4.42 (t, 1H, J = 8.5a 
Hz, b), 4.61 (dd, 1H, J = 2.5, 8.6e Hz, e), 5.01 (dd, 1H, J = 
4.1, 8.6e Hz, e), 5.94 (t, 1H, J = 3.9 Hz, f). 
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13
C NMR (75.5MHz, CDCl3) δ: 22.1, 22.3, 25.3, 26.4, 50.5, 54.1, 63.2, 64.9, 85.5, 133.9. 
FTIR max cm
-1
: 1742, 2924 
HRMS (ESI): calcd. for C13H16N2O3 [M+Na]
+
 271.1058 found 271.1045 
 
 
3.2.18 cyclohexanecarboxaldehyde oxime 
 
The title compound was prepared by a modification of the procedure of Liu.
55
 
A solution of sodium carbonate (1.988 g, 18.75 mmol) in water (30mL) was added 
dropwise to a stirred solution of hydroxylamine hydrochloride (2.327 g, 33.48 mol) and 
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cyclohexanecarboxaldehyde (3.00 g, 26.80 mmol) in water (20 mL). The reaction mixture 
was allowed to stir for 2 hours, followed by extraction with ether (3 x 80 mL). The 
organic phases were combined, washed with water (50 mL), dried over magnesium 
sulfate and concentrated in vacuo and used directly for the next step (3.115 g, 92 %). 
1
H NMR (500 MHz, CDCl3) δ: 1.15-1.34 (m, 4H, c, d), 1.44 (m, 2H, e), 1.69-1.79 (m, 4H, 
c, d), 2.22 (m, 1H, b), 7.31 (d, 1H, J = 5.1 Hz, a), 9.12 (s, 
1H, f). 
13
C NMR (125.7 MHz, CDCl3) δ: 25.5 (4), 25.9 (5), 30.2 (3), 38.5 (2), 156.1 (1). 
LRMS (ES+): 127 ([MH]
+
) 
 
 
3.2.19 (3aS,8aR,8bR)-3-cyclohexyl-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5] 
pyrrolo[3,4-d]isoxazol-6-one (2.22) 
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To a stirred solution of (S)-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (100 
mg, 0.800 mmol), cyclohexanecarboxaldehyde oxime (112 mg, 0.880 mmol) and 
triethylamine (0.134 mL, 0.960 mmol) in dichloromethane (10 mL), 8 % aqueous sodium 
hypochlorite (10 mL) was added dropwise over 15 min at 0
o
C. The reaction mixture was 
allowed to stir for 12 hours, the aqueous layer was separated before extraction with 
dichloromethane (3 x 50 mL). The organic phases were combined and washed with water 
(2 x 50 mL), then dried over magnesium sulfate and concentrated in vacuo. Diethyl ether 
(30 mL) was added to the residue and then filtered, the solid residue was rinsed with 
diethyl ether (30 mL) and then recrystallised from methanol to give (3aS,8aR,8bR)-3-
cyclohexyl-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5]pyrrolo[3,4-d]isoxazol-6-one 
(2.22) as a white solid (52 mg, 26 %). 
Melting range: 230.4 - 232.7
 o
C. 
[α]  
  
= -184.4 (c= 0.95, CHCl3) 
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1
H NMR (500 MHz, CDCl3) δ: 1.20 - 1.26 (td, 2H, J = 2.5, 12.0h Hz, i), 1.29 - 1.34 (td, 
2H, J = 3.0h, 12.3h Hz, g), 1.48 (qd, 1H, J = 3.0g, 12.3g Hz, 
h), 1.68 (d, 1H, J = 12.9 Hz, h), 1.78 (m, 2H, g), 1.92 (d, 2H, 
12.0i Hz, h), 2.37 (tt, 1H, 3.3, 11.2 Hz, j), 3.26 (dd, 1H, J = 
8.1a, 12.8c Hz, c), 3.90 (t, 1H, J = 8.1c Hz, a), 4.01 (d, 1H, J 
= 12.8c Hz, c), 4.05 (m, 1H, d), 4.46 (t, 1H, J = 8.5 Hz, b), 
4.65 (dd, 1H, J = 2.4d, 8.7e Hz, e), 5.00 (dd, 1H, J = 4.6d, 
8.7e Hz, e). 
13
C NMR (125.7 MHz, CDCl3) δ: 25.8 (10), 30.0 (11), 31.2 (9), 35.9 (8), 48.4 (3), 55.7 
(1), 62.7 (4), 64.1 (5), 83.6 (2), 160.8 (7), 162.4 (6). 
FTIR max cm
-1
: 1726, 2854, 2927. 
HRMS (ESI): calcd. for C13H18N2O3 [M+Na]
+
 273.1215 found 273.1201 
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3.2.20 4-ethyl benzaldehyde oxime 
 
The title compound was prepared by a modification of the procedure of Liu.
55 
A solution of sodium carbonate (820 mg, 7.731 mmol) in water (20mL) was added to a 
stirred solution of hydroxylamine hydrochloride (959 mg, 13.80 mol) and 4-ethyl 
benzaldehyde (1.480 g, 11.40 mmol) in water (30 mL) dropwise. The reaction mixture 
was allowed to stir for 2 hours, followed by extraction with ether (3 x 50 mL). The 
organic phases were combined, washed with water (50 mL), dried over magnesium 
sulfate, concentrated in vacuo and used directly for the next step (1.583 g, 96 %). 
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1
H NMR (500 MHz, CDCl3) δ: 1.26 (t, 3H, J = 7.6d Hz, c), 2.68 (q, 2H, J = 7.6c Hz, d), 
7.23 (app. d, 2H, J = 7.4a Hz, b), 7.51 (app. d, 2H, J = 7.4b 
Hz, a), 8.16 (s, 1H, e). 
13
C NMR (125.7 MHz, CDCl3) δ: 15.3 (6), 28.8 (5), 127.1 (3), 128.3 (1), 129.4 (2), 146.6 
(4), 150.3 (7). 
FTIR max cm
-1
: 1679, 2557, 2844 
LRMS (ES+): 149 ([MH]
+
) 
 
3.2.21 (3aS,8aR,8bR)-3-(4-ethylphenyl)-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5] 
pyrrolo[3,4-d]isoxazol-6-one (2.23) 
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To a stirred solution of (S)-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (164 
mg, 1.311 mmol), ethyl benaldehyde oxime (234 mg, 1.573 mmol) and triethylamine 
(0.220 mL, 1.573 mmol) in dichloromethane (10 mL), 8 % aqueous sodium hypochlorite 
(10 mL) was added dropwise over 15 min at 0 
o
C. The reaction mixture was allowed to 
stir for 12 hours, the aqueous layer was separated before extraction with dichloromethane 
(3 x 50 mL). The organic phases were combined and washed with water (2 x 50 mL), 
then dried over magnesium sulfate and concentrated in vacuo. Diethyl ether (30 mL) was 
added to the residue and then filtered, the solid residue was rinsed with diethyl ether (30 
mL), and then recrystallised from methanol to give (3aS,8aR,8bR)-3-(4-ethylphenyl)-
3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5]pyrrolo [3,4-d]isoxazol-6-one (2.23) as a 
white solid (128 mg, 36 %). 
Melting range: 260.2 – 263.6 oC. 
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[α]  
  
= -318.3 (c= 0.35, CHCl3) 
1
H NMR (500 MHz, CDCl3) δ: 1.25 (t, 3H, J = 7.5h Hz, i), 2.68 (q, 2H, J = 7.5i Hz, h), 
3.45 (dd, 1H, J = 8.2a, 12.6b Hz, b), 4.05 (d, 1H, 12.6b Hz, 
b), 4.19 (m, 1H, d), 4.33 (t, 1H, J = 8.2b Hz, a), 4.52 (t, 1H, 
J = 8.7e Hz, e), 4.74 (d, 1H, J = 8.7e Hz, e), 5.22 (dd, 1H, J 
= 4.1, 8.2 Hz, c), 7.25 (app. d, 2H, J = 8.1f Hz, g), 7.53 
(app. d, 2H, J = 8.1g Hz, f). 
13
C NMR (125.7 MHz, CDCl3) δ: 15.1 (13), 28.6 (12), 49.3 (4), 54.5 (1), 62.5 (3), 64.3 
(5), 85.1 (2), 109.8 (8), 124.7 (11), 126.9 (9), 128.3 (10), 
147.0 (7), 157.5 (6). 
FTIR max cm
-1
: 1736, 2968. 
HRMS (ESI): calcd. for C15H16N2O3 [M+Na]
+
 295.1059 found 295.1043 
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3.2.22 3,3-dimethylbutanal oxime 
 
The title compound was prepared by a modification of the procedure of Liu.
55 
A solution of sodium carbonate (371 mg, 3.50 mmol) in water (20mL) was added 
dropwise to a stirred solution of hydroxylamine hydrochloride (434 mg, 6.25 mmol) and 
3,3-dimethylbutanal (500 mg, 5.00 mmol) in water (10 mL). The reaction mixture was 
allowed to warm to room temperature for 2 hours, followed by extraction with ether (3 x 
50 mL). The organic phases were combined, washed with water (50 mL), dried over 
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magnesium sulfate, concentrated in vacuo and used directly for the next step (428 mg, 74 
%). 
3.2.23 (3aS,8aR,8bR)-3-(2,2-dimethylpropyl)-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo [3', 
4':1,5]pyrrolo[3,4-d]isoxazol-6-one (2.24) 
 
To a stirred solution of (S)-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.1) (100 
mg, 0.800 mmol), 3,3-dimethylbutanal oxime (129 mg, 1.119 mmol) and triethylamine 
(0.134 mL, 0.960 mmol) in dichloromethane (10 mL), 8 % aqueous sodium hypochlorite 
(10 mL) was added dropwise over 15 min at 0
o
C. The reaction mixture was allowed to 
stir for 12 hours, the aqueous phase was separated before extraction with 
dichloromethane (3 x 50 mL). The organic phases were combined, washed with water (2 
x 50 mL), then dried over magnesium sulfate and concentrated in vacuo. Diethyl ether 
(30 mL) was added to the residue and then filtered, the solid residue was rinsed with 
diethyl ether (30 mL) and then recrystallised from methanol give (3aS,8aR,8bR)-3-(2,2-
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dimethylpropyl)-3a,8,8a,8b-tetrahydro-4H-[1,3]oxazolo[3',4':1,5] pyrrolo[3,4-d] isoxazol 
-6-one (2.24) as a white solid (45 mg, 24 %). 
Melting range: 199.5 – 205.2 oC. 
[α]  
  
= -162 (c= 0.40, CHCl3) 
1
H NMR (300MHz, CDCl3) δ: 1.03 (s, 9H, g), 2.17 (d, 1H, J = 14.8f Hz, f), 2.45 (d, 1H, J 
= 14.8f Hz, f), 3.26 (dd, 1H, J = 7.9a, 12.8b Hz, b), 3.91 (t, 
1H, J = 7.9b Hz, a), 4.02 - 4.08 (m, 2H, d, b), 4.48 (t, 1H, J 
= 8.7e Hz, e), 4.69 (dd, 1H, J = 2.4, 8.7e Hz, e), 5.02 (dd, 
1H, J = 4.8, 8.5 Hz, c). 
13
C NMR (75.5MHz, CDCl3) δ: 29.8 (10), 31.4 (9), 39.1 (4), 48.3 (1), 58.6 (8), 62.7 (3), 
64.5 (6), 83.0 (2), 125.2 (7), 157.0 (5). 
FTIR max cm
-1
: 1730, 2955 
HRMS (ESI): calcd. for C12H18N2O3 [M+Na]
+
 261.1215 found 261.1202 
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3.2.24 (6R,7R,7aR)-6-acetyl-7-hydroxytetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one 
(2.25) 
 
Raney nickel (1 spatula, approx. 10-20 mg) was added to a stirred solution of ethyl 
(3aS,8aR,8bR)-6-oxo-3a,8,8a,8b-tetrahydro-4H[1,3]oxazolo[3',4':1,5]pyrrolo[3,4-d] 
isoxazole-3-carboxylate (2.20) (680 mg, 3.732 mmol) and boric acid (485 mg, 7.838 
mmol) in a 5:1 mixture of methanol and water (30 mL). The reaction mixture was 
allowed to stir for 8 hours under hydrogen atmosphere. The Raney nickel was removed 
by filtration, the solution was concentrated in vacuo and used directly for the next step 
(406 mg, 40 %). Rf (EtOAc) = 0.16 
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3.2.25 (7aS)-6-acetyl-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.26) 
 
 
p-Toluenesulfonic acid monohydrate (3.5 mg, 18.5 umol) was added to a stirred mixture 
of (6R,7R,7aR)-6-acetyl-7-hydroxytetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.25) 
(171 mg, 0.924 mmol) and toluene (15 mL). The reaction was heated under reflux for 2 
hours with a Dean-Stark apparatus. The reaction mixture was concentrated in vacuo and 
the residue was purified by flash column chromatography on silica gel, eluting with neat 
diethyl ether to give (7aS)-6-acetyl-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one 
(2.26) as a brown oil (64 mg, 42 %).  
Rf (Et2O) = 0.09 
[α]  
  
= -93.4 (c= 0.69, CHCl3) 
1
H NMR (500 MHz, CDCl3) δ: 2.34 (s, 3H, e), 3.97 (d, 1H, J = 15.6d Hz, d), 4.33 (dd, 1H, 
J = 4.9, 8.7c Hz, c), 4.56 (d, 1H, J = 15.6d Hz, d), 4.63 (t, 1H, 
J = 8.7c Hz, c), 4.90 (m, 1H, b), 6.67 (s, 1H, a). 
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13
C NMR (125.7 MHz, CDCl3) δ: 26.9 (8), 53.5 (3), 65.4 (4), 67.3 (5), 138.0 (1), 145.0 
(2), 162.5 (6), 193.8 (7). 
FTIR max cm
-1
: 1666, 1732, 2919. 
HRMS (ESI): calcd. for C8H9NO3 [M+Na]
+
 190.0475 found 190.0483. 
 
 
3.2.26 (7aS)-6-[1-hydroxy-1-methyl-2-(trimethylsilyl)ethyl]-5,7a-dihydro-1H-pyrrolo[1,2 
-c][1,3]oxazol-3-one (2.33) 
 
Trimethylsilylmethyl lithium (1.0 M in pentane, 1.08 mL, 1.079 mmol) was added to a 
stirred suspension of anhydrous CeCl3 (310 mg, 1.258 mmol) in THF (10 mL) at -78 
o
C, 
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the suspension was allowed to stir for a further 1 hour before adding (7aS)-6-acetyl-5,7a-
dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.26) (120 mg, 0.719 mmol) in dry THF 
(10 mL). The reaction was allowed to warm to room temperature over 1 hour followed by 
stirring for a further 2 hours. The resulting mixture was concentrated in vacuo and re-
diluted in DCM (30 mL) then washed with H2O (30 mL). The aqueous layer was 
extracted with DCM (3 x 30 mL), the combined organic layers were dried over MgSO4 
and concentrated in vacuo. The residue was purified by flash column chromatography on 
silica gel, eluting with 2:1 diethyl ether / n-hexane to give (7aS)-6-[1-hydroxy-1-methyl-
2-(trimethylsilyl)ethyl]-5,7a-dihydro-1H-pyrrolo[1,2c][1,3]oxazol-3-one (2.33) as a 
brown oil (124 mg, 68 %). 
Rf (Et2O / n-hexane 2:1) = 0.19 
[α]  
  
= +32.8 (c= 0.67, CHCl3) 
1
H NMR (500 MHz, CDCl3) δ: 0.05 (2 x s, 9H, g), 1.13 (2 x s, 2H, f), 1.44 (s, 3H, e), 3.86 
(d, 1H, J = 15.4d Hz, d), 4.21 (m, 1H, c), 4.38 (d, 1H, J = 
15.4d Hz, d), 4.56 (t, 1H, J = 8.3 Hz, c), 4.73 (m, 1H, b), 
5.64 (s, 1H, a). 
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13
C NMR (125.7 MHz, CDCl3) δ: 0.1 (9), 29.6 (10), 30.3 (8), 31.9 (3), 54.1 (4), 64.8 (5), 
68.8 (7), 120.3 (1), 125.4 (2), 154.2 (6). 
FTIR max cm
-1
: 1741, 2921, 3450. 
HRMS (ESI): calcd. for C12H21NO3Si [M+Na]
+
 190.0475 found 190.0483. 
 
 
3.2.28 (6S,7R,7aS)-6-acetyl-7-phenyltetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.36) 
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Phenyllithium solution (2.0 M in dibutyl ether, 1.26 mL, 2.515 mmol) was added to a 
stirred suspension of copper bromide (180 mg, 1.257 mmol) in anhydrous diethyl ether 
(10 mL) dropwise at -10
 o
C. The suspension was allowed to stir for 15 minutes before 
cooling to -78
 o
C. A solution of (7aS)-6-acetyl-5,7a-dihydro-1H-pyrrolo[1,2-
c][1,3]oxazol-3-one (2.26) (100 mg, 0.599 mmol) in anhydrous diethyl ether (10 mL) was 
added to the reaction mixture dropwise before allowing to warm to room temperature for 
12 hours, the resulting mixture was poured into an ice / saturated ammonium chloride 
solution mixture. The organic phase was washed with saturated ammonium chloride 
solution (2 x 50 mL) and the combined aqueous phases were extracted with diethyl ether 
(2 x 50 mL). The organic phases were combined and washed with saturated sodium 
chloride solution (50 mL), then dried over magnesium sulfate and concentrated in vacuo. 
The residue was purified by flash column chromatography on silica gel, eluting with 3:1 
diethyl ether / n-hexane to give (6S,7R,7aS)-6-acetyl-7-phenyltetrahydro-1H-pyrrolo[1,2-
c][1,3]oxazol-3-one (2.36) as a brown oil (32 mg, 22 %). Rf (Et2O / n-hexane 3:1) = 0.15 
[α]  
  
= +92.4 (c= 0.52, CHCl3) 
1
H NMR (600 MHz, CDCl3) δ: 1.94 (s, 3H, e), 3.09 (t, 1H, J = 10.1b Hz, f), 3.48 (td, 1H, 
J = 7.4d, 9.9d Hz, a), 3.62 (dd, 1H, J = 9.9a, 11.8d Hz, d), 
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3.90 (dd, 1H, J = 7.4a, 11.8d Hz, d), 3.99 (ddd, 1H, J = 2.5c, 
7.6j, 10.1f Hz, b), 4.15 (dd, 1H, J = 2.5b, 9.3j Hz, c), 4.32 (dd, 
1H, J = 7.6b, 9.3c Hz, j), 7.20 (d, 2H, J = 4.7 Hz, g), 7.25 (t, 
1H, J = 7.5h Hz, i), 7.31 (t, 2H, J = 7.5i Hz, h). 
13
C NMR (125.7 MHz, CDCl3) δ: 30.0 (8), 48.0 (1), 52.6 (3), 60.2 (2), 65.9 (4), 66.5 (5), 
127.7 (10), 128.1 (12), 129.3 (11), 136.8 (9), 160.9 (6), 
204.9 (7). 
FTIR max cm
-1
: 1708, 1746, 2912. 
HRMS (ESI): calcd. for C14H15NO3 [M+Na]
+
 268.0944 found 268.0940. 
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3.2.27 (6S,7S,7aS)-6-acetyl-7-butyltetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one (2.37) 
 
n-Butyllithium (2.5 M in pentane, 1.00mL, 2.515 mmol) was added to a stirred 
suspension of copper bromide (180 mg, 1.257 mmol) in anhydrous diethyl ether (10 mL) 
dropwise at -10
 o
C. The suspension was allowed to stir for 15 minutes before cooling to -
78
 o
C, a solution of (7aS)-6-acetyl-5,7a-dihydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-one 
(2.26) (100 mg, 0.599 mmol) in anhydrous diethyl ether (10 mL) was added to the 
reaction mixture dropwise before allowing to warm to room temperature for 12 hours. 
The resulting mixture was poured into an ice / saturated ammonium chloride solution 
mixture and the organic phase was washed with saturated ammonium chloride solution (2 
x 50 mL). The combined aqueous phases were extracted with diethyl ether (2 x 50 mL), 
the organic phases were combined and washed with saturated sodium chloride solution 
(50 mL), then dried over magnesium sulfate and concentrated in vacuo. The residue was 
purified by flash column chromatography on silica gel, eluting with 2:1 diethyl ether / n-
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hexane to give  (6S,7S,7aS)-6-acetyl-7-butyltetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-
one (2.37) as a brown oil (70 mg, 52 %). Rf (Et2O / n-hexane 3:1) = 0.18 
[α]  
  
= +77.3 (c= 0.65, CHCl3) 
1
H NMR (600 MHz, CDCl3) δ: 0.85 (t, 3H, J = 7.3i Hz, h), 1.12 – 1.24 (m, 2H, i), 1.24 – 
1.32 (m, 2H, j) 1.34 (dddd, 1H, J = 5.4i, 8.2f, 10.8i, 13.6g Hz, 
g) 1.49 (dddd, 1H, J = 5.1i, 6.0f, 11.4i, 13.5g Hz, g), 2.18 (s, 
3H, e), 2.17 – 2.22 (m, 1H, f), 2.94 (ddd, 1H, J = 6.7d, 8.8f, 
9.8d Hz, a), 3.47 (dd, 1H, J = 9.8a, 11.9d Hz, d), 3.63 (ddd, 
1H, J = 3.5c, 7.8k, 9.0g Hz, b), 3.68 (dd, 1H, J = 6.6a, 11.9d 
Hz, d), 4.22 (dd, 1H, J = 3.5b, 9.1k Hz, c), 4.50 (dd, 1H, J = 
7.9b, 9.1c Hz, k). 
13
C NMR (125.7 MHz, CDCl3) δ: 13.8 (12), 22.8 (11), 29.1 (8), 30.2 (10), 31.8 (9), 46.5 
(1), 47.7 (3), 58.9 (2), 64.8 (4), 67.5 (5), 160.6 (6), 206.3 (7). 
FTIR max cm
-1
: 1707, 1747, 2926. 
HRMS (ESI): calcd. for C12H19NO3 [M+Na]
+
 248.1257 found 248.1248. 
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